glp 1 mash approval FDA grants the first GLP-1 for liver disease treatment Semaglutide, a GLP-1R agonist, is

This is particularly beneficial for individuals with type 2 diabetes, as it can lead to better blood sugar management alongside weight loss

Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime

Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome

Book your virtual consultation today

SGLT2 inhibition and clinical heart and kidney protection The heart and kidney protective effects of SGLT2 inhibitors were first demonstrated in three large cardiovascular outcome trials (CVOT) exclusively comprising participants with T2DM

This test maps 14 metabolic pathways and 49 peptides, including key variants in the GLP1R gene (rs6923761) and GIPR pathway that influence how aggressively your body responds to GLP-1 therapy